# A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer

> **NCT07358676** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 25 (estimated)

## Conditions studied

- Small Cell Lung Cancer (SCLC)
- SCLC, Extensive Stage

## Interventions

- **COMBINATION_PRODUCT:** Bemotuzumab + Anlotinib + Chemotherapy + Radiotherapy

## Key facts

- **NCT ID:** NCT07358676
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2027-01-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07358676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07358676, "A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-27 from https://api.ai-analytics.org/clinical/NCT07358676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*